Evidence map›Paper›PMID 40186773›Full record

ArticleBioprocess and biosystems engineering2025

Scaling up biofilm bioreactors for enhanced menaquinone-7 production.

Aydin Berenjian, Ehsan Mahdinia, Ali Demirci

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aydin BerenjianDepartment of Chemical and Biological Engineering, Colorado State University, Fort Collins, CO, 80523, USA.
Ehsan MahdiniaStack Family Center for Biopharmaceutical Education and Training, Albany College of Pharmacy and Health Sciences, Albany, NY, 12203, USA.
Ali DemirciDepartment of Agricultural and Biological Engineering, 221 Agricultural Engineering Building, Pennsylvania State University, University Park, PA, 16802, USA. demirci@psu.edu.

Funding

USDA National Institute of Food and Agriculture Federal Appropriations Project #PEN04850 (Accession #7005668) and Project #PEN04876 (Accession #7005757)
6 · The paper itself

Abstract

The health benefits of menaquinone-7 (MK-7) are well-established, and its production through fermentation techniques is widespread. Our team developed an innovative biofilm reactor utilizing Bacillus subtilis natto cells to foster biofilm growth on plastic composite supports to produce MK-7. The scalability of this biofilm reactor from a 2-L benchtop scale in our laboratory and its potential for commercial applications pose significant unresolved questions. Therefore, the current research was aimed to scale up the biofilm reactor from bench scale (2-L) to the pilot scale (30-L) bioreactor. Three strategies were evaluated to understand their impact on MK-7 biosynthesis during bioreactor volume expansion: volumetric oxygen mass transfer coefficient (k

Indexed as

Bacillus subtilisBiofilmsBioreactorsVitamin K 2Fermentationmenaquinone 7Vitamin K 2Biofilm reactorCommercial productionMenaquinone-7Scale-upVolumetric mass-transfer coefficient

Identifiers

PMID40186773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.